Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study
Authors: Igarashi Atsuyuki , Katsunuma Toshio , Matsumura Takayo , Komazaki Hiroshi ,   for the Nemolizumab-JP04 Study Group, Takahashi Hidetoshi , Miura Katsushi , Horino Satoshi , Yoshihara Shigemi , Maeda Shozo , Akashi Masayuki , Hamahata Yuko , Nezu Yoko , Masuda Kei , Shirakawa Seigo , Katsunuma Toshio , Ohya Yukihiro , Yanagida Noriyuki , Tadaki Hiromi , Fukuzawa Masao , Kaneko Hideo , Takahashi Kazuhiro , Funato Michinori , Futamura Masaki , Kodera Masanari , Takasato Yoshihiro , Fujisawa Takao , Kume Akihiro , Taketani Takeshi , Murakami Youko , Wakatsuki Masatoshi , Igawa Satomi , Tomiita Minako , Suzuki Shuichi , Narita Masami , Yoshida Koichi , Kondo Yasuto , Kiyomasu Takahiro , Takemura Yutaka , Manki Akira , Hide Michihiro , Tanaka Akio , Tezuka Junichiro , Ikeda Masanori , Yamaide Fumiya , Nakano Taiji 
Published: July 2023

Background

Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥ 13 years. However, data relating to its efficacy and safety in younger children (aged &lt; 13 years) have been lacking.

Objectives

To evaluate the efficacy and safety of nemolizumab, administered concomitantly with topical agents, in Japanese paediatric patients (aged 6–12 years) with AD and inadequately controlled moderate-to-severe pruritus.

Methods

This was a randomized, placebo-controlled, double-blind, parallel-group, multicentre, 16-week, phase III study. Patients aged ≥ 6 and &lt; 13 years, with confirmed AD, and an inadequate pruritic response despite treatment with topical agents and oral antihistamines were randomly assigned (1 : 1) to receive nemolizumab 30 mg or placebo every 4 weeks (Q4W). The primary efficacy endpoint was the change in the weekly mean 5-level itch score from baseline to week 16; secondary efficacy endpoints were related to pruritus, indicators for AD and QoL. Safety was assessed via adverse events (AEs) and laboratory test results.

Results

In total, 89 patients were enrolled, received either nemolizumab 30 mg (n = 45) or placebo (n = 44) Q4W, and completed the study. The mean patient age was 9.1 (SD 1.9) years, and mean duration of AD was 8.5 (2.7) years. The change in 5-level itch score from baseline to week 16 showed a statistically significant difference in the nemolizumab treatment group (−1.3) compared with placebo (−0.5; least-squares mean difference −0.8, 95% confidence interval −1.1 to −0.5; P &lt; 0.0001). Improvements with nemolizumab were observed from the second day of administration. Secondary endpoints were in favour of nemolizumab. No AEs resulted in discontinuation, and the overall safety profile in patients aged 6–12 years was comparable with that in older patients (aged ≥ 13 years) with AD.

Conclusions

Nemolizumab is a potential new treatment option for paediatric patients with AD whose pruritus has not been sufficiently improved with topical treatments and antihistamines.